Ekvakard - Instructions For Use, Price, Reviews, Tablets 5 + 5 Mg

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2023-12-15 07:39

Equacard

Ekvakard: instructions for use and reviews

1. 1. Release form and composition
2. 2. Pharmacological properties
3. 3. Indications for use
4. 4. Contraindications
5. 5. Method of application and dosage
6. 6. Side effects
7. 7. Overdose
8. 8. Special instructions
9. 9. Application during pregnancy and lactation
10. 10. Use in childhood
11. 11. In case of impaired renal function
12. 12. For violations of liver function
13. 13. Use in the elderly
14. 14. Drug interactions
15. 15. Analogs
16. 16. Terms and conditions of storage
17. 17. Terms of dispensing from pharmacies
18. 18. Reviews
19. 19. Price in pharmacies

Latin name: Ekvacard

ATX code: C09BB03

Active ingredient: amlodipine (Amlodipine) + lisinopril (Lisinopril)

Producer: Micro Labs Limited (India)

Description and photo updated: 30.11.2018

Prices in pharmacies: from 214 rubles.

Buy

Ekvakard is a combined antihypertensive agent.

Release form and composition

The drug is produced in the form of tablets: flat-cylindrical, round, with a chamfer, with a risk on one side, pink (5 mg) or white (10 mg) color (10 pieces in a blister, in a cardboard box of 1, 2, 3 or 10 blisters and instructions for use of Ekvakard).

1 tablet contains:

• active ingredients: amlodipine - 5 mg, lisinopril - 5 or 10 mg;
• additional components: magnesium stearate, corn starch, lactose, povidone, talc; additionally, for tablets with a dosage of lisinopril 5 mg - crimson dye (Ponso 4R).

Pharmacological properties

Pharmacodynamics

Ekvacard is a combined preparation containing an angiotensin-converting enzyme (ACE) inhibitor and a slow calcium channel blocker (BMCC).

Lisinopril is an ACE inhibitor that reduces the formation of angiotensin II from angiotensin I, which leads to a direct decrease in the release of aldosterone. Lisinopril prevents the degradation of bradykinin and increases the production of prostaglandins (PG). The substance lowers blood pressure (BP), total peripheral vascular resistance (OPSR), pulmonary capillary pressure and preload. Against the background of chronic heart failure (CHF), lisinopril leads to an increase in the minute blood volume and an increase in myocardial tolerance to exercise. Provides expansion of arteries to a greater extent than veins, with prolonged use helps to reduce hypertrophy of the heart muscle and the walls of resistive type arteries, as well as improve blood supply to the ischemic myocardium. Some of the effects of the drug are explained by the effect on the tissue renin-angiotensin-aldosterone system (RAAS).

In patients with CHF, due to the action of ACE inhibitors, life expectancy increases, and in patients who have suffered acute myocardial infarction, not accompanied by clinical manifestations of heart failure, the rate of progression of left ventricular dysfunction decreases.

The effect of lisinopril begins to manifest itself 1 hour after administration, the antihypertensive effect, depending on the size of the dose taken, reaches a maximum after 6-7 hours and is observed for 24 hours. In the treatment of arterial hypertension, the therapeutic effect of the active substance is noted already in the first days of the course, a permanent effect appears after 1–2 months. In the case of a sudden discontinuation of lisinopril, there was no significant increase in blood pressure. The drug reduces albuminuria, in the presence of diabetes mellitus, it does not affect the blood glucose level and does not cause an increase in hypoglycemia.

Amlodipine is a derivative of dihydropyridine, BMCC, which has antianginal and antihypertensive effects, blocking calcium channels, reducing the flow of calcium ions through the membranes into the cell (to a greater extent in the cells of vascular smooth muscles than in cardiomyocytes). The antianginal activity of the substance is caused by the expansion of the peripheral and coronary arteries and arterioles: as a result of the expansion of the peripheral arterioles, the systemic vascular resistance decreases, in patients with angina pectoris, the severity of myocardial ischemia decreases and the afterload on the heart decreases, and myocardial oxygen demand decreases.

By expanding the coronary arteries and arterioles in the ischemic and unchanged areas of the myocardium, amlodipine increases the supply of oxygen to it (especially against the background of vasospastic angina pectoris), prevents spasm of the coronary arteries (including those caused by smoking).

With stable angina pectoris, this substance in a single daily dose leads to an increase in the time to the onset of an angina attack and ischemic ST-segment depression, an increase in exercise tolerance, a decrease in the frequency of angina attacks and the consumption of nitrates, including nitroglycerin. Amlodipine demonstrates a long-term dose-dependent antihypertensive effect due to a direct vasodilating effect on the smooth muscles of the vascular walls. Taking a single dose in the treatment of arterial hypertension provides a significant decrease in blood pressure (in the supine and standing position) for 24 hours, while orthostatic hypotension is rarely recorded.

Amlodipine does not lead to a decrease in the left ventricular ejection fraction and helps to reduce the degree of myocardial hypertrophy of the latter. The substance also does not affect the contractility and conductivity of the heart muscle, does not provoke a reflex increase in the heart rate (HR), blocks platelet aggregation, increases the glomerular filtration rate (GFR), exhibits a weak natriuretic effect.

Against the background of diabetic nephropathy, amlodipine does not increase the severity of microalbuminuria, does not change the level of lipids in the blood plasma and does not have any negative effect on the metabolism of substances. It leads to a clinically significant decrease in blood pressure 6–10 hours after administration, the effect is recorded within 24 hours. Amlodipine can be used in the treatment of patients with diabetes mellitus, bronchial asthma and gout.

Reception of Ekvacard, which includes lisinopril and amlodipine, avoids the appearance of possible undesirable effects caused by the counter-regulation of one of the active substances. BMCC, for example, providing direct expansion of arterioles, can cause fluid and sodium retention in the body and thus contribute to the activation of the RAAS, and an ACE inhibitor leads to the suppression of this process.

Pharmacokinetics

After oral administration, lisinopril is absorbed from the gastrointestinal tract (GIT) by about 25%; the variability in different patients can be from 6 to 60%. The maximum concentration (C _max) of the active substance in the blood plasma is recorded after 7 hours, its absorption does not depend on food intake, and the bioavailability is 29%. The connection with plasma proteins is insignificant, the substance almost does not penetrate through the placental and blood-brain barriers (BBB), does not undergo biotransformation in the body. Lisinopril is excreted unchanged by the kidneys, its half-life (T _½) is 12.6 hours, its clearance is 50 ml / min, and the serum level is reduced in two stages. Against the background of CHF, absorption and clearance of the drug decrease, and the bioavailability is 16%.

In the elderly, lisinopril C _max in plasma and the area under the concentration-time curve (AUC) are 2 times higher than those in young patients.

In patients with renal insufficiency [with creatinine clearance (CC) below 30 ml / min], the level of the active substance in plasma is several times higher than in healthy volunteers, with an increase in the period of reaching C _max in blood plasma and an increase in T _½.

In the presence of cirrhosis of the liver, the bioavailability of lisinopril decreases by 30%, and clearance - by 50%.

After oral administration of amlodipine, it is slowly absorbed from the gastrointestinal tract. The absolute bioavailability averages 64%, in the blood serum C _{max of the} substance is recorded after 6-9 hours. Equilibrium concentrations (C _ss) are observed after 7–8 days of treatment. Food intake does not affect the absorption of the drug. The average volume of distribution (V _d) is 21 l / kg, which confirms that the drug is mostly distributed in the tissues, less in the blood. The substance contained in the blood is almost completely (95%) bound to plasma proteins.

Amlodipine is slowly but actively metabolized in the liver; there is no significant effect of primary passage. Metabolites do not demonstrate significant pharmacological activity. After oral administration of 1 dose, T _½ can be 35-50 hours, with repeated use - about 45 hours. Approximately 60% of an orally administered dose of amlodipine is excreted by the kidneys, mainly in the form of metabolites, 20–25% - with bile through the intestine, 10% - unchanged. The total clearance of the substance is 0.116 ml / s / kg (0.42 l / h / kg, 7 ml / min / kg).

In persons over 65 years old, when compared with young patients, the elimination of amlodipine is slower (T _½ - 65 hours), but this effect has no clinical significance. The kinetics of amlodipine is not significantly affected by impaired renal function.

In patients with impaired liver function, lengthening T _½ suggests that in the body with prolonged use of the agent, the cumulation will be higher, T _½ can reach 60 hours. Amlodipine passes through the BBB; it is not excreted during hemodialysis.

Pharmacokinetic interaction between the active ingredients of Ekvacard is unlikely. The value of C _max and the period of its achievement, AUC and T _{½ of the} drug are not subject to changes in comparison with the indicators of each of the active substances separately. Both active substances circulate in the body for a long time, which allows you to take the drug once a day.

Indications for use

Equacard is recommended for the treatment of essential hypertension in patients for whom combination therapy is indicated.

Contraindications

Absolute:

• cardiogenic shock;
• severe arterial hypotension (systolic blood pressure below 90 mm Hg);
• unstable angina (except for Prinzmetal's angina);
• acute myocardial infarction (during the first 28 days);
• hypertrophic obstructive cardiomyopathy or hemodynamically significant aortic / mitral stenosis;
• a history of indications of angioedema, including those associated with therapy with other ACE inhibitors;
• idiopathic and / or hereditary angioedema;
• age up to 18 years;
• pregnancy and lactation;
• glucose-galactose malabsorption, lactase deficiency and lactose intolerance;
• hypersensitivity to any component of the drug or to other dihydropyridine derivatives or other ACE inhibitors.

Relative (you should take Ekvacard tablets with extreme caution):

• coronary insufficiency, ischemic heart disease (IHD);
• arterial hypotension;
• heart failure in the stage of decompensation;
• CHF of non-ischemic etiology of III and IV functional class according to the classification of the New York Association of Cardiologists (NYHA);
• sick sinus syndrome (severe tachycardia, bradycardia);
• acute myocardial infarction (after the first 28 days);
• aortic / mitral stenosis;
• cerebrovascular lesions (including insufficiency of cerebral circulation);
• oppression of bone marrow hematopoiesis;
• systemic connective tissue diseases (including scleroderma, systemic lupus erythematosus);
• renal and / or hepatic impairment;
• bilateral stenosis of the renal arteries or stenosis of an artery of a solitary kidney with aggravated azotemia;
• condition after kidney transplantation;
• hemodialysis using high-flow dialysis membranes (AN69) (with concomitant treatment with ACE inhibitors, anaphylactoid reactions were recorded; in such cases, a different type of dialysis membrane or another antihypertensive agent should be used);
• azotemia;
• hyperkalemia;
• primary hyperaldosteronism;
• conditions that lead to a decrease in the volume of circulating blood (BCC) (including diarrhea, vomiting);
• elderly age;
• adherence to a diet with reduced consumption of table salt.

Ekvakard, instructions for use: method and dosage

Ekvakard tablets are taken orally 1 pc. Once a day.

The tablet should be taken with a sufficient amount of liquid, food intake does not affect the effect of the drug.

At the beginning of the course of treatment, symptomatic arterial hypotension may occur, most often observed against the background of violations of the water-electrolyte balance caused by previous treatment with diuretics. The use of diuretics should be discontinued 2-3 days before starting Ekvacard. If this cancellation is impossible, the drug should be taken 1 time per day, ½ tablet at a dosage of 5 mg + 5 mg, after which it is necessary to monitor the patient's condition for several hours due to the risk of symptomatic arterial hypotension.

Side effects

Adverse reactions recorded when using lisinopril:

• hematopoietic system and lymphatic system: rarely - a decrease in the level of hemoglobin, hematocrit; extremely rare - erythropenia, neutropenia, leukopenia, eosinophilia, thrombocytopenia, hemolytic anemia, lymphadenopathy, agranulocytosis, autoimmune diseases;
• cardiovascular system: often - a significant decrease in blood pressure, orthostatic hypotension; infrequently - palpitations, tachycardia, acute myocardial infarction, Raynaud's syndrome; rarely - chest pain, aggravation of CHF symptoms, tachycardia, bradycardia, violation of atrioventricular conduction;
• respiratory system: often - cough; infrequently - rhinitis; extremely rare - shortness of breath, sinusitis, allergic alveolitis / eosinophilic pneumonia, bronchospasm;
• nervous system: often - headache, dizziness; infrequently - sleep disorders, mood lability, paresthesia, stroke; rarely - asthenic syndrome, drowsiness, convulsive twitching of the muscles of the limbs and lips, confusion;
• digestive system: often - vomiting, diarrhea; infrequently - changes in taste, indigestion, abdominal pain; rarely - dry mouth; extremely rare - anorexia, jaundice (hepatocellular / cholestatic), pancreatitis, liver failure, hepatitis, interstitial edema;
• urinary system: often - impaired renal function; infrequently - acute renal failure, uremia; extremely rare - oliguria, anuria, proteinuria;
• skin: infrequently - rash, itching; rarely - alopecia, urticaria, psoriasis, angioedema of the face, tongue, lips, larynx, extremities (with the development of these symptoms, it is necessary to stop taking the drug and establish medical supervision until their complete regression); extremely rare - increased sweating, pemphigus, vasculitis, photosensitivity, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis;
• reproductive system: infrequently - impotence; rarely - gynecomastia;
• musculoskeletal system: rarely - myalgia, arthralgia / arthritis;
• metabolism: extremely rare - hypoglycemia;
• laboratory indicators: infrequently - an increase in the activity of hepatic transaminases, an increase in the level of urea in the blood, hyperkalemia, hypercreatininemia; rarely - hyponatremia, hyperbilirubinemia, increased erythrocyte sedimentation rate, false positive test responses for antinuclear antibodies.

Adverse reactions observed during therapy with amlodipine:

• cardiovascular system: often - a feeling of palpitations, peripheral edema (ankles and feet), flushing of the skin of the face; infrequently - a significant decrease in blood pressure, vasculitis, orthostatic hypotension; rarely - the development / aggravation of the course of CHF; extremely rare - shortness of breath, migraine, fainting, chest pain, pulmonary edema, ventricular tachycardia, atrial fibrillation, bradycardia, myocardial infarction;
• hematopoietic and lymphatic systems: extremely rarely - leukopenia, thrombocytopenic purpura, thrombocytopenia;
• digestive system: often - abdominal pain, nausea; infrequently - thirst, dryness of the oral mucosa, changes in bowel movements (including flatulence, constipation), vomiting, diarrhea, dyspepsia, anorexia; rarely - increased appetite, gingival hyperplasia; extremely rarely - increased activity of hepatic transaminases, hyperbilirubinemia, jaundice (usually cholestatic), gastritis, pancreatitis, hepatitis;
• nervous system: often - drowsiness, increased fatigue, headache (mainly at the beginning of the course), dizziness; infrequently - emotional lability, insomnia, unusual dreams, nervousness, anxiety, increased excitability, depression, general malaise, increased sweating, tremor, paresthesia, hypesthesia, asthenia, peripheral neuropathy; rarely - agitation, apathy, convulsions; extremely rare - amnesia, ataxia;
• reproductive system and mammary glands: infrequently - impotence, gynecomastia;
• urinary system: infrequently - painful urge to urinate, nocturia, pollakiuria; extremely rare - polyuria, dysuria;
• musculoskeletal system: infrequently - back pain, muscle cramps, arthralgia, myalgia, arthrosis; rarely - myasthenia gravis;
• respiratory system: infrequently - rhinitis, shortness of breath; extremely rare - cough;
• metabolism: extremely rare - hyperglycemia;
• sense organs: infrequently - eye pain, visual impairment, disturbance of accommodation, diplopia, conjunctivitis, xerophthalmia, ringing in the ears; extremely rare - parosmia;
• allergic reactions: rarely - rash (including maculopapular, erythematous), itching; extremely rarely - urticaria, erythema multiforme, angioedema;
• skin: infrequently - alopecia; rarely - dermatitis; extremely rare - a violation of skin pigmentation, cold clammy sweat, xeroderma;
• others: infrequently - chills, weight loss / increase, nosebleeds, taste perversion.

Overdose

Symptoms of an overdose of lisinopril may include: dryness of the oral mucosa, constipation, drowsiness, increased irritability, anxiety, a marked decrease in blood pressure, imbalance in water and electrolyte balance, palpitations, dizziness, rapid breathing, tachycardia, bradycardia, cough, renal failure, delay urination. In this condition, gastric lavage, laxatives and enterosorbents are prescribed; there is no specific antidote. Intravenous (IV) infusion of 0.9% sodium chloride solution is also recommended. With the development of therapy-resistant bradycardia, the use of a pacemaker is necessary. It is required to control blood pressure and indicators of water and electrolyte balance. Lisinopril can be removed from the systemic circulation through hemodialysis.

Symptoms of an amlodipine overdose can be: a pronounced decrease in blood pressure with the risk of reflex tachycardia and excessive peripheral vasodilation (significant and persistent arterial hypotension, including the development of shock and death). In case of an overdose of this substance, a gastric lavage is prescribed, and the intake of activated carbon (especially within 2 hours after an overdose). Measures are recommended to maintain the activity of the cardiovascular system, control the BCC, diuresis and indicators of heart and lung function. In order to restore vascular tone in the absence of contraindications, vasoconstrictor agents are administered. Intravenous administration of calcium gluconate eliminates the effects of calcium channel blockade. Hemodialysis is not effective.

special instructions

Ekvakardom therapy can be started only after the correction of hyponatremia and restoration of the BCC.

Due to the possible significant decrease in blood pressure and the development of symptomatic arterial hypotension after the first dose of the drug, careful monitoring of blood pressure is required.

In the event of arterial hypotension, the patient should be given a horizontal position and, if necessary, an intravenous infusion of sodium chloride solution should be prescribed to replenish the volume of the circulating fluid. When using the drug in patients with cerebrovascular insufficiency, ischemic heart disease, in whom, with a sharp decrease in blood pressure, the threat of developing myocardial infarction or stroke is aggravated, similar rules should also be followed.

During treatment, it is necessary to control body weight and consumption of table salt, following an appropriate diet. Periodic monitoring of peripheral blood is also necessary due to the risk of agranulocytosis.

It is required to maintain oral hygiene and be observed by the dentist in order to prevent the appearance of bleeding, soreness and gingival hyperplasia.

While taking Ekvacard, edema of the tongue, larynx or epiglottis may occur, leading to obstruction of the airways, as a result of this, with the development of this phenomenon, it is urgent to inject subcutaneously a solution of epinephrine / adrenaline (1: 1000 at a dose of 0.3-0.5 ml) and / or take measures to ensure airway patency. With the localization of edema only on the face and lips, antihistamines may be prescribed.

Before surgery (including dental surgery), it is required to inform the surgeon / anesthetist about the use of ACE inhibitors. During major surgical operations or when prescribing general anesthetics with an antihypertensive effect, lisinopril can inhibit the formation of angiotensin II associated with compensatory renin release. With arterial hypotension, in this case, blood pressure is normalized by increasing the BCC.

Influence on the ability to drive vehicles and complex mechanisms

Patients driving vehicles and other complex mechanisms need to be careful while using the drug due to the risk of drowsiness, dizziness and hypotension.

Application during pregnancy and lactation

During pregnancy, therapy with Ekvacard is contraindicated. If pregnancy is detected during treatment, the drug should be stopped immediately and switched to another antihypertensive drug approved for use by pregnant women.

Treatment with ACE inhibitors in the II-III trimesters of pregnancy can cause an excessive decrease in blood pressure in the fetus, hyperkalemia, hypoplasia of the skull bones, renal failure, and intrauterine death. There are no data on the adverse effects of an antihypertensive agent on the fetus when used in the first trimester. Newborns and infants whose mothers took ACE inhibitors during pregnancy should be closely monitored for the timely detection of oliguria, a significant decrease in blood pressure, and hyperkalemia.

The efficacy and safety of treatment with amlodipine in pregnant women has not been established, therefore, the use of this drug during pregnancy is allowed only when the expected benefit to the mother significantly outweighs the risk to fetal health.

There is no information on the penetration of lisinopril into breast milk. It is not known whether amlodipine is excreted in breast milk, but it has been established that other BMCCs, which are dihydropyridine derivatives, are excreted in breast milk. Women who are breastfeeding should not take Ekvacard. If taking the drug is necessary during lactation, then breastfeeding should be discontinued.

Pediatric use

Patients under 18 years of age are contraindicated to use Ekvacard.

With impaired renal function

In the presence of impaired renal function, the drug should be used with caution. It is recommended to prescribe a dose of 5 + 5 mg Ekvacard. The maintenance dose must be selected taking into account the tolerability of the treatment.

In patients with circulatory failure, dehydration, hyponatremia, bilateral renal artery stenosis or stenosis of an artery of a single kidney, the use of Ekvacard can cause impairment of renal function and acute renal failure (reversible after interruption of treatment). Patients in this group are recommended to monitor renal function, as well as the plasma concentration of potassium and sodium in the blood.

For violations of liver function

In the presence of violations of the liver, the drug should be taken with caution. It is recommended to prescribe a dose of 5 + 5 mg Ekvacard.

Use in the elderly

In elderly patients, therapy should be carried out with caution.

Drug interactions

Interaction reactions possible with the combined use of lisinopril with other drugs / agents:

• potassium-sparing diuretics (triamterene, spironolactone, eplerenone, amiloride), cyclosporine, potassium preparations, salt substitutes containing potassium: the risk of hyperkalemia is aggravated, especially in case of impaired renal function; these combinations are possible only as directed by a physician and with regular monitoring of renal function and serum potassium concentration;
• diuretics and other antihypertensive drugs: the antihypertensive effect is potentiated;
• non-steroidal anti-inflammatory drugs (NSAIDs), including selective inhibitors of cyclooxygenase-2 (COX-2); sympathomimetics, estrogens: the hypotensive effect is weakened;
• NSAIDs (including COX-2), ACE inhibitors: the level of potassium in the blood serum increases, and renal function may deteriorate (the disorders are usually reversible);
• lithium preparations: the elimination of lithium slows down, which leads to an increase in its plasma concentration (reversible) and aggravates the threat of undesirable phenomena; requires regular monitoring of serum lithium levels;
• antacids, cholestyramine: absorption of lisinopril from ZhK'G decreases;
• barbiturates, vasodilators, tricyclic antidepressants, antipsychotics (antipsychotics), beta-blockers, BMCC: the antihypertensive effect is enhanced;
• ethanol: the effect of lisinopril is potentiated;
• insulin and antidiabetic oral agents: the risk of hypoglycemia is exacerbated;
• procainamide, allopurinol, cytostatics: leukopenia may occur;
• gold preparations with intravenous administration (sodium aurothiomalate): it is possible to develop a symptom complex, including facial flushing, vomiting, nausea and a decrease in blood pressure, when combined with ACE inhibitors.

Interaction reactions that can be observed with the combined use of amlodipine with other drugs / agents:

• beta-blockers: possible exacerbation of CHF;
• ACE inhibitors, alpha-blockers, thiazide diuretics: no negative effects are noted;
• NSAIDs (including indomethacin): no clinically significant interaction is observed;
• ACE inhibitors, nitrates, thiazide and loop diuretics: antianginal and hypotensive effects are enhanced;
• alpha ₁ -adrenergic blockers, antipsychotics, isoflurane: the antihypertensive effect increases;
• antiretroviral drugs (ritonavir): increases plasma concentration of amlodipine;
• sildenafil (a single dose of 100 mg), aluminum or magnesium-containing antacids, cimetidine, grapefruit juice: there is no significant effect on the pharmacokinetic parameters of amlodipine in patients with arterial hypertension;
• erythromycin: the C _{max of} amlodipine increases by 22% in young patients and by 50% in the elderly;
• antiarrhythmic drugs that cause prolongation of the QT interval (amiodarone, quinidine): the severity of the negative inotropic effect of these drugs may increase when combined with some BMCC;
• ethanol-containing drinks: no effect on the pharmacokinetics of ethanol with a single / repeated use of amlodipine at a dose of 10 mg is recorded;
• atorvastatin (at a dose of 80 mg): there are no significant changes in the pharmacokinetics of this substance when combined with amlodipine at a dose of 10 mg;
• cyclosporine: its pharmacokinetics does not change;
• calcium preparations: it is possible to reduce the effect of BMCC;
• isoflurane, antipsychotics: the hypotensive effect of dihydropyridine derivatives is enhanced;
• lithium preparations: there may be an aggravation of the manifestations of neurotoxicity (diarrhea, vomiting, nausea, ataxia, tinnitus, tremor);
• digoxin: no effect on the serum concentration of this substance and its renal clearance is observed;
• warfarin: no significant effect on the effect of this substance (prothrombin time) is noted;
• warfarin, phenytoin, digoxin, indomethacin: in vitro, under the influence of amlodipine, the binding to plasma proteins of these substances does not change.

Analogs

Equacard's analogues are: Tenliza, De-Kriz, Equator, Lisinopril plus, Eklamiz, etc.

Terms and conditions of storage

Store in a place protected from light and out of reach of children, at a temperature not exceeding 25 ° C.

The shelf life is 3 years.

Terms of dispensing from pharmacies

Dispensed by prescription.

Reviews about Equacard

On medical sites, the few reviews about Equacard are in most cases positive. Many patients note the effectiveness of the drug in the treatment of essential hypertension. However, along with reviews of the pronounced positive dynamics observed during treatment, there are many reviews with complaints about the lack of expected results of therapy due to the development of a number of side effects, such as a significant decrease in blood pressure, dizziness, headache, and nausea.

Price for Ekvakard in pharmacies

The price for Ekvakard for a pack containing 30 tablets can be:

• dosage 5 mg + 5 mg - 310-390 rubles;
• dosage 5 mg + 10 mg - 399-511 rubles.

Ekvakard: prices in online pharmacies

Drug name Price Pharmacy

Ekvacard 5 mg + 5 mg tablets 30 pcs. 214 r Buy

Ekvacard tablets 5mg + 5mg 30 pcs. 305 RUB Buy

Ekvacard 5 mg + 10 mg tablets 30 pcs. 376 r Buy

Ekvacard tablets 5mg + 10mg 30 pcs. 406 r Buy

Maria Kulkes Medical journalist About the author

Education: First Moscow State Medical University named after I. M. Sechenov, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!